PALO ALTO, Calif. (AP) — Affymax Inc. received a $10 million milestone
payment from partner Takeda Pharmaceutical Co., the company said Wednesday,
after federal regulators accepted an application for the potential anemia
treatment peginesatide.
Affymax, based in Palo Alto, Calif., said the companies are developing
peginesatide, formerly known as Hematide, to treat anemia in patients with
chronic kidney failure. The companies plan to co-market the drug in the United
States if it receives approval. Takeda, which is based in Japan, will sell the
drug outside the United States.
The companies said in May they asked the U.S. Food and Drug Administration to
approve the drug. FDA reviews typically take 10
months.
